首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Authors:Chun-Sick Eom  Christie Y Jeon  Ju-Won Lim  Eun-Geol Cho  Sang Min Park  Kang-Sook Lee
Institution:From the Department of Family Medicine (Eom, Lim, Cho, Park), Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University College of Medicine (Park), Seoul, Republic of Korea; the Department of Epidemiology (Jeon), Harvard School of Public Health, Boston, Mass.; and the Department of Preventive Medicine (Lee), College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Abstract:

Background

Observational studies and randomized controlled trials have yielded inconsistent findings about the association between the use of acid-suppressive drugs and the risk of pneumonia. We performed a systematic review and meta-analysis to summarize this association.

Methods

We searched three electronic databases (MEDLINE PubMed], Embase and the Cochrane Library) from inception to Aug. 28, 2009. Two evaluators independently extracted data. Because of heterogeneity, we used random-effects meta-analysis to obtain pooled estimates of effect.

Results

We identified 31 studies: five case–control studies, three cohort studies and 23 randomized controlled trials. A meta-analysis of the eight observational studies showed that the overall risk of pneumonia was higher among people using proton pump inhibitors (adjusted odds ratio OR] 1.27, 95% confidence interval CI] 1.11–1.46, I2 90.5%) and histamine2 receptor antagonists (adjusted OR 1.22, 95% CI 1.09–1.36, I2 0.0%). In the randomized controlled trials, use of histamine2 receptor antagonists was associated with an elevated risk of hospital-acquired pneumonia (relative risk 1.22, 95% CI 1.01–1.48, I2 30.6%).

Interpretation

Use of a proton pump inhibitor or histamine2 receptor antagonist may be associated with an increased risk of both community- and hospital-acquired pneumonia. Given these potential adverse effects, clinicians should use caution in prescribing acid-suppressive drugs for patients at risk.Recently, the medical literature has paid considerable attention to unrecognized adverse effects of commonly used medications and their potential public health impact.1 One group of medications in widespread use is acid-suppressive drugs, which represent the second leading category of medication worldwide, with sales totalling US$26.9 billion in 2005.2Over the past 40 years, the development of potent acid-suppressive drugs, including proton pump inhibitors, has led to considerable improvements in the treatment of acid-related disorders of the upper gastrointestinal tract.3 Experts have generally viewed proton pump inhibitors as safe.4 However, potential complications such as gastrointestinal neoplasia, malabsorption of nutrients and increased susceptibility to infection have caused concern.5Of special interest is the possibility that acid-suppressive drugs could increase susceptibility to respiratory infections because these drugs increase gastric pH, thus allowing bacterial colonization.6,7 Several previous studies have shown that treatment with acid-suppressive drugs might be associated with an increased risk of respiratory tract infections8 and community-acquired pneumonia in adults6,7 and children.9 However, the association between use of acid-suppressive drugs and risk of pneumonia has been inconsistent.1013Given the widespread use of proton pump inhibitors and histamine2 receptor antagonists, clarifying the potential impact of acid-suppressive therapy on the risk of pneumonia is of great importance to public health.14 Previous meta-analyses have focused on the role of acid-suppressive drugs in preventing stress ulcer,11,13,15 but none have examined pneumonia as the primary outcome.The aim of this study was to summarize the association between the use of acid-suppressive drugs and the risk of pneumonia in observational studies and randomized controlled trials.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号